Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Can-Fite BioPharma ( (CANF) ) has shared an update.
On June 30, 2025, Can-Fite BioPharma Ltd. held its Annual General Meeting of Shareholders, where all six proposals presented were approved by the required majority. These proposals, detailed in a prior notice and proxy statement, reflect the company’s strategic decisions and governance practices, potentially impacting its operational and market positioning.
The most recent analyst rating on (CANF) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Neutral.
Can-Fite BioPharma’s overall stock score reflects significant financial challenges and a bearish technical outlook. The company’s negative profitability, declining revenues, and reliance on external financing are major concerns. Technical indicators suggest caution, while valuation metrics indicate ongoing losses, affecting investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. operates in the biopharmaceutical industry, focusing on the development of small molecule drugs for the treatment of autoimmune inflammatory diseases, cancer, and liver diseases. The company is headquartered in Ramat Gan, Israel.
Average Trading Volume: 212,202
Technical Sentiment Signal: Sell
Current Market Cap: $15.3M
For a thorough assessment of CANF stock, go to TipRanks’ Stock Analysis page.